Huarong Rongde Asset Management appeared to be the VC, which was created in 2006. The venture was found in Asia in China. The leading representative office of defined VC is situated in the Beijing.
The typical case for the fund is to invest in rounds with 4 participants. Despite the Huarong Rongde Asset Management, startups are often financed by Kunlun. The meaningful sponsors for the fund in investment in the same round are Sino-Ocean Capital, Deutsche Bank, Clearwater Capital Partners LLC.
Among the various public portfolio startups of the fund, we may underline Nash Work For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Coworking, Office Administration.
The important activity for fund was in 2018. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually.
Fund Name | Location |
AdOutlet.com | New York, New York, United States |
Alterfin | Belgium, Brussels Hoofdstedelijk Gewest, Brussels-Capital |
Altimeter | California, San Francisco, United States |
Barings Equity Partners | China, Hong Kong, Hong Kong Island |
Bittrex Support | Liechtenstein, Vaduz, Vaduz |
Black Kite Capital | - |
C2 Capital Management | Chicago, Illinois, United States |
Expo Live | Dubai, United Arab Emirates |
Falcon Network | - |
Havoc Capital | - |
HKB Capital | - |
Kips | Chiyoda, Japan |
Park Ten Capital | - |
Peesh Venture Capital | Bangalore, India, Karnataka |
Shanghai Xiecheng Heli Touzi Qiye | China, Qingpu, Shanghai |
Sunflower Investment | China, Futian, Guangdong |
Tobon VC | China, Hangzhou, Zhejiang |
Upper90 | New York, New York, United States |
Wideblue | Glasgow, Glasgow City, United Kingdom |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Gensciences | $123M | 04 Mar 2021 | Nantong, Jiangsu, China | ||
Hinova Pharma | $154M | 06 Oct 2020 | Qingyang District, Sichuan, China | ||
$278M | 29 Apr 2020 | China, Shanghai | |||
Nash Work | $77M | 07 Jun 2018 | China, Beijing | ||
Oriental Arc | $463K | 07 May 2014 | Gusu District, Jiangsu, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Gensciences | $123M | 04 Mar 2021 | Nantong, Jiangsu, China | ||
Hinova Pharma | $154M | 06 Oct 2020 | Qingyang District, Sichuan, China | ||
$278M | 29 Apr 2020 | China, Shanghai | |||
Nash Work | $77M | 07 Jun 2018 | China, Beijing | ||
Oriental Arc | $463K | 07 May 2014 | Gusu District, Jiangsu, China |